Focus
respiratory syncytial virus
LATEST
Children Have Higher Hospitalizations From RSV Than Omicron or Influenza
A recent research paper found that hospitalization rates were over 80 percent for RSV and only 30 percent for omicron and the flu.
|
Pfizer Failed to Disclose Risks of Preterm Birth and Neonatal Death to Pregnant Women in RSV Vaccine Trial
A BMJ investigation revealed Pfizer was studying preterm births as an “adverse event of special interest” in RSV trial, but didn’t inform pregnant participants.
|
COVID-19 Is Less Frequent and Severe in Infants Than Other Respiratory Viruses, Study Finds
A study found infants under 2 months of age were less likely to experience SARS-CoV-2 infection and less severe illness compared with other respiratory viruses.
|
RSV Treatment for Infants in Limited Supply: CDC
The CDC has recommended prioritizing infants at the highest risk for severe RSV owing to the short supply of monoclonal antibody nirsevimab.
|
After Decades of Setbacks, First-Ever RSV Vaccine Approved: A Closer Look
The FDA approved the first-ever RSV vaccine for adults aged 60 and over—almost 60 years after the first RSV vaccine trial was called off due to two deaths.
|
Children Have Higher Hospitalizations From RSV Than Omicron or Influenza
A recent research paper found that hospitalization rates were over 80 percent for RSV and only 30 percent for omicron and the flu.
|
Pfizer Failed to Disclose Risks of Preterm Birth and Neonatal Death to Pregnant Women in RSV Vaccine Trial
A BMJ investigation revealed Pfizer was studying preterm births as an “adverse event of special interest” in RSV trial, but didn’t inform pregnant participants.
|
COVID-19 Is Less Frequent and Severe in Infants Than Other Respiratory Viruses, Study Finds
A study found infants under 2 months of age were less likely to experience SARS-CoV-2 infection and less severe illness compared with other respiratory viruses.
|
RSV Treatment for Infants in Limited Supply: CDC
The CDC has recommended prioritizing infants at the highest risk for severe RSV owing to the short supply of monoclonal antibody nirsevimab.
|
After Decades of Setbacks, First-Ever RSV Vaccine Approved: A Closer Look
The FDA approved the first-ever RSV vaccine for adults aged 60 and over—almost 60 years after the first RSV vaccine trial was called off due to two deaths.
|